APP and Alzheimer disease: Laboratory studies indicated that in APP/PS1 mouse models of AD, the genetic overexpression of apoA-I prevented the development of cognitive impairment, whereas the deficiency of apoA-I exacerbated cognitive impairments (Lewis et al., 2010).